Decision Analysis of the COVID-19 Vaccines

1Woo PC, Huang Y, Lau SK, Yuen KY "Coronavirus genomics and bioinformatics analysis". Viruses. August 2010. 2 (8): 1804–20. doi:10.3390/v2081803. PMC 3185738. PMID 21994708. Coronaviruses possess the largest genomes (26.4 kb (ThCoV HKU12) to 31.7 kb (SW1)) among all known RNA viruses (Figure 1) (2,13,16). Woo PC Huang Y Lau SK Yuen KY "Coronavirus genomics and bioinformatics analysis" Viruses August 2010 2 8 180420 doi10.3390/v2081803 PMC 3185738. PMID 21994708. Coronaviruses possess the largest genomes (26.4 kb (ThCoV HKU12) to 31.7 kb (SW1)) among all known RNA viruses (Figure 1) (2,13,16)318573821994708Open DOISearch in Google Scholar

2Novel Ehrlichia Strain Infecting Cattle Tick Amblyomma neumanni, Argentina, 2018 Lucía Fargnoli, Camilo Fernandez, Lucas D. Monje Author affiliation: Instituto de Ciencias Veterinarias del Litoral, UNL-CONICET, Esperanza, Argentina DOI: https://doi.org/10.3201/eid2605.190940 Novel Ehrlichia Strain Infecting Cattle Tick Amblyomma neumanni, Argentina, 2018 Lucía Fargnoli, Camilo Fernandez, Lucas D. Monje Author affiliation: Instituto de Ciencias Veterinarias del Litoral, UNL-CONICET, Esperanza Argentina DOI https://doi.org/10.3201/eid2605.19094010.3201/eid2605.190940718190632310066Search in Google Scholar

3Coronaviruses. Niaid.nih.gov 2021. Retrieved 23 May 2021, from https://www.niaid.nih.gov/diseases-conditions/coronaviruses Coronaviruses Niaid.nih.gov 2021 Retrieved 23 May 2021, from https://www.niaid.nih.gov/diseases-conditions/coronavirusesSearch in Google Scholar

4Parry, N. COVID-19 and pets: When pandemic meets panic. Forensic Science International 2020: Reports, 2, 100090. https://doi.org/10.1016/j.fsir.2020.100090 Parry N COVID-19 and pets: When pandemic meets panic Forensic Science International 2020 Reports, 2, 100090 https://doi.org/10.1016/j.fsir.2020.10009010.1016/j.fsir.2020.100090Search in Google Scholar

5Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. "The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2". Nature Microbiology. March 2020. 5 (4): 536–544. Doi:10.1038/s41564-020-0695-z. PMC 7095448. PMID 32123347. Gorbalenya AE Baker SC Baric RS de Groot RJ Drosten C Gulyaeva AA et al "The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2" Nature Microbiology March 2020 5 4 536544 Doi10.1038/s41564-020-0695-z PMC 7095448. PMID 32123347709544832123347Open DOISearch in Google Scholar

6"Coronavirus disease named Covid-19". BBC News Online. 11 February 2020. Archived from the original on 15 February 2020. Retrieved 15 February 2020. "Coronavirus disease named Covid-19" BBC News Online 11 February 2020. Archived from the original on 15 February 2020. Retrieved 15 February 2020Search in Google Scholar

7Ozsahin, I., Sekeroglu, B., Musa, M., Mustapha, M., & Uzun Ozsahin, D. Review on Diagnosis of COVID-19 from Chest CT Images Using Artificial Intelligence. Computational and Mathematical Methods in Medicine, 2020, 1-10. https://doi.org/10.1155/2020/9756518 Ozsahin I. Sekeroglu B. Musa M. Mustapha M. & Uzun Ozsahin D Review on Diagnosis of COVID-19 from Chest CT Images Using Artificial Intelligence Computational and Mathematical Methods in Medicine 2020 110 https://doi.org/10.1155/2020/975651810.1155/2020/9756518751998333014121Search in Google Scholar

8"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 2021-04-24. "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS Johns Hopkins University Retrieved 2021-04-24Search in Google Scholar

9"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 2021-04-24. "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS Johns Hopkins University Retrieved 2021-04-24Search in Google Scholar

10Santacroce, L., Charitos, I., Carretta, D., De Nitto, E., & Lovero, R. The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection. Journal of Molecular Medicine, 2020. 99(1), 93-106. https://doi.org/10.1007/s00109-020-02012-8 Santacroce L. Charitos I. Carretta D. De Nitto E. & Lovero R. The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection Journal of Molecular Medicine 2020 991 93106 https://doi.org/10.1007/s00109-020-02012-810.1007/s00109-020-02012-8771036833269412Search in Google Scholar

11Cohen J (2020-01-26). "Wuhan seafood market may not be the source of the novel virus spreading globally". ScienceMag American Association for the Advancement of Science. (AAAS). Archived from the original on 2020-01-27. Retrieved 2020-01-29. Cohen J 2020-01-26 "Wuhan seafood market may not be the source of the novel virus spreading globally" ScienceMag American Association for the Advancement of Science. (AAAS) Archived from the original on 2020-01-27. Retrieved 2020-01-2910.1126/science.abb0611Search in Google Scholar

12Eschner K (2020-01-28). "We're still not sure where the COVID-19 really came from". Popular Science. Archived from the original on 2020-01-30. Retrieved 2020-01-30. Eschner K 2020-01-28 "We're still not sure where the COVID-19 really came from" Popular Science. Archived from the original on 2020-01-30. Retrieved 2020-01-3010.51449/AJPR.2020.1101Search in Google Scholar

13Clinical characteristics of COVID-19. European Centre for Disease Prevention and Control. (2021). Retrieved 1 May 2021, from https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical Clinical characteristics of COVID-19. European Centre for Disease Prevention and Control 2021 Retrieved 1 May 2021, from https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinicalSearch in Google Scholar

14Benefits of Getting a COVID-19 Vaccine. Centers for Disease Control and Prevention. (2021). Retrieved 23 May 2021, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html Benefits of Getting a COVID-19 Vaccine. Centers for Disease Control and Prevention 2021 Retrieved 23 May 2021, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.htmlSearch in Google Scholar

15Luo, R., Delaunay‐Moisan, A., Timmis, K., & Danchin, A. SARS‐CoV ‐2 biology and variants: anticipation of viral evolution and what needs to be done. Environmental Microbiology, 2021. 23(5), 2339-2363. https://doi.org/10.1111/1462-2920.15487 Luo R. Delaunay‐Moisan A. Timmis K. & Danchin A. SARS‐CoV ‐2 biology and variants: anticipation of viral evolution and what needs to be done Environmental Microbiology 2021 235 23392363 https://doi.org/10.1111/1462-2920.1548710.1111/1462-2920.15487825135933769683Search in Google Scholar

16Doulberis, M., Papaefthymiou, A., Kotronis, G., Gialamprinou, D., Soteriades, E., & Kyriakopoulos, A. et al. Does COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”?. Medicina, 2021.57(3), 253. https://doi.org/10.3390/medicina57030253 Doulberis M. Papaefthymiou A. Kotronis G. Gialamprinou D. Soteriades E. & Kyriakopoulos A. et al Does COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”? Medicina 2021573 253 https://doi.org/10.3390/medicina5703025310.3390/medicina57030253799935633803295Search in Google Scholar

17Brans, J., & Vincke, P. Note- A Preference Ranking Organization Method. Management Science, 1985, 31(6), 647-656. https://doi.org/10.1287/mnsc.31.6.647 Brans J. & Vincke P Note- A Preference Ranking Organization Method Management Science 1985 316 647656 https://doi.org/10.1287/mnsc.31.6.64710.1287/mnsc.31.6.647Search in Google Scholar

18Macharis, C., Springael, J., De Brucker, K., & Verbeke, A. PROMETHEE and AHP: The design of operational synergies in multi-criteria analysis. European Journal of Operational Research, 2004. 153(2), 307-317. https://doi.org/10.1016/s0377-2217 (03)00153-x. Macharis C. Springael J. De Brucker K. & Verbeke A. PROMETHEE and AHP: The design of operational synergies in multi-criteria analysis European Journal of Operational Research 2004 1532 307317 https://doi.org/10.1016/s0377-2217(03)00153-x10.1016/S0377-2217(03)00153-XSearch in Google Scholar

19Wouters, O., Shadlen, K., Salcher-Konrad, M., Pollard, A., Larson, H., Teerawattananon, Y., & Jit, M. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet, 2021. 397(10278), 1023-1034. https://doi.org/10.1016/s0140-6736 (21)00306-8. Wouters O. Shadlen K. Salcher-Konrad M. Pollard A. Larson H. Teerawattananon Y. & Jit M Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment The Lancet 2021 39710278 10231034 https://doi.org/10.1016/s0140-6736(21)00306-810.1016/S0140-6736(21)00306-8Search in Google Scholar

20Abdullah, L., Chan, W., & Afshari, A.. Application of PRO-METHEE method for green supplier selection: a comparative result based on preference functions. Journal of Industrial Engineering International, 2018. 15(2), 271-285. https://doi.org/10.1007/s40092-018-0289-z Abdullah L. Chan W. & Afshari A. Application of PRO-METHEE method for green supplier selection: a comparative result based on preference functions Journal of Industrial Engineering International 2018 152 271285 https://doi.org/10.1007/s40092-018-0289-z10.1007/s40092-018-0289-zSearch in Google Scholar

21Nakajima, Y., Fujii, T., Mukai, K., Ishida, A., Kato, M., & Takahashi, M. et al. Anatomically safe sites for intramuscular injections: a cross-sectional study on young adults and cadavers with a focus on the thigh. Human Vaccines & Immunotherapeutics, 2019. 16(1), 189-196. https://doi.org/10.1080/21645515.2019.1646576 Nakajima Y. Fujii T. Mukai K. Ishida A. Kato M. & Takahashi M. et al Anatomically safe sites for intramuscular injections: a cross-sectional study on young adults and cadavers with a focus on the thigh Human Vaccines & Immunotherapeutics 2019 161 189196 https://doi.org/10.1080/21645515.2019.164657610.1080/21645515.2019.1646576Search in Google Scholar

22Cdc.gov (2021). Retrieved 23 May 2021, from https://www.cdc.gov/vaccines/hcp/conversations/downloads/vacsafe-understand-color-office.pdf Cdc.gov 2021 Retrieved 23 May 2021, from https://www.cdc.gov/vaccines/hcp/conversations/downloads/vacsafe-understand-color-office.pdfSearch in Google Scholar

23Ryzhikov, A., Ryzhikov, Е., Bogryantseva, M., Usova, S., Danilenko, E., & Nechaeva, E. et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity, 2021. 11(2), 283-296. https://doi.org/10.15789/2220-7619-asb-1699 Ryzhikov A. Ryzhikov Е. Bogryantseva M. Usova S. Danilenko E. & Nechaeva E. et al A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II) Russian Journal of Infection and Immunity 2021 112 283296 https://doi.org/10.15789/2220-7619-asb-169910.15789/2220-7619-ASB-1699Search in Google Scholar

24Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19 - Full Text View - ClinicalTrials. gov. Clinicaltrials.gov 2021. Retrieved 23 May 2021, from https://clinicaltrials.gov/ct2/show/NCT04780035 Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19 - Full Text View - ClinicalTrials. gov Clinicaltrials.gov 2021 Retrieved 23 May 2021, from https://clinicaltrials.gov/ct2/show/NCT04780035Search in Google Scholar

25All you need to know about COVID-19 and Vaccines (National Institute for Communicable Diseases). 2021. 3(1), 77. https://doi.org/10.18772/26180197.2021.v3n1a16 All you need to know about COVID-19 and Vaccines (National Institute for Communicable Diseases) 2021 31 77 https://doi.org/10.18772/26180197.2021.v3n1a1610.18772/26180197.2021.v3n1a16Search in Google Scholar

26How Gamaleya’s Vaccine Works. Nytimes.com 2021. Retrieved 23 May 2021, from https://www.nytimes.com/interactive/2021/health/gamaleya-covid-19-vaccine.html How Gamaleya’s Vaccine Works Nytimes.com 2021 Retrieved 23 May 2021, from https://www.nytimes.com/interactive/2021/health/gamaleya-covid-19-vaccine.htmlSearch in Google Scholar

27FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. U.S. Food and Drug Administration. 2021. Retrieved 23 May 2021, from https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. U.S. Food and Drug Administration. 2021 Retrieved 23 May 2021, from https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covidSearch in Google Scholar

28Information about the Pfizer-BioNTech COVID-19 Vaccine. Centers for Disease Control and Prevention. 2021. Retrieved 23 May 2021, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html Information about the Pfizer-BioNTech COVID-19 Vaccine Centers for Disease Control and Prevention 2021 Retrieved 23 May 2021, from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.htmlSearch in Google Scholar

29Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. October 2020. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281. Xia S Zhang Y Wang Y Wang H Yang Y Gao GF et al "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial" The Lancet. Infectious Diseases October 2020 21 1 3951 doi10.1016/s1473-3099(20)30831-8.PMC7561304.PMID33069281Open DOISearch in Google Scholar

30Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al.. "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. September 2020.324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505. Xia S Duan K Zhang Y Zhao D Zhang H Xie Z et al "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials" JAMA September 2020324 10 951960 doi10.1001/jama.2020.15543 PMC 7426884. PMID 32789505742688432789505Open DOISearch in Google Scholar

31Vergara, Eva. "Big Chile study finds Chinese vaccine slashes COVID deaths". ABC News. Retrieved 16 April 2021. Vergara Eva "Big Chile study finds Chinese vaccine slashes COVID deaths" ABC News Retrieved 16 April 2021Search in Google Scholar